Pacific Biosciences of California Inc. (NASDAQ:PACB) saw a downside of -1.97% to close Monday at $11.94 after subtracting -$0.24 on the day. The 5-day average trading volume is 5,348,480 shares of the company’s common stock. It has gained $13.36 in the past week and touched a new high 1 time within the past 5 days. An average of 3,701,135 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,787,318.
PACB’s 1-month performance is -3.32% or -$0.41 on its low of $11.44 reached on 08/03/23. The company’s shares have touched a 52-week low of $4.97 and high of $14.55, with the stock’s rally to the 52-week high happening on 07/18/23. YTD, PACB has achieved 45.97% or $3.76 and has reached a new high 19 times. However, the current price is down -17.94% from the 52-week high price.
Insider Transactions
PACB stock investors last saw insider trading activity on May 18.Farmer Michele () most recently sold 5,165 shares at $12.59 per share on May 18. This transaction cost the insider $65,027. Director, Ericson William W., sold 7,541 shares at a price of $8.90 on Mar 15. Then, on Mar 03, HENRY CHRISTIAN O sold 13,769 shares at a price of $9.49 per share. This transaction amounted to $130,709.
Valuation Metrics
PACB stock has a beta of 1.63. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 19.32 while the price-to-book (PB) in the most recent quarter is 4.17.
Pacific Biosciences of California Inc.’s quick ratio for the period ended June 29 was 3.50, with the current ratio over the same period at 3.70. As well, the company’s long term debt to equity for the quarter ending June 29 was 1.30, while the total debt to equity was 1.30. In terms of profitability, the gross margin trailing 12 months is 32.60%. The trailing 12-month EBITDA margin is -224.08%. The firm’s gross profit as reported stood at $49.03 million against revenue of $128.3 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Pacific Biosciences of California Inc.’s cash and short-term investments amounted to $620.58 million against total debt of $939.06 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -2.23% to -$69.83 million, while revenue of -$88.02 million was -26.05% off the previous quarter. Analysts expected PACB to announce -$0.32 per share in earnings in its latest quarter, but it posted -$0.28, representing a 12.50% surprise. EBITDA for the quarter stood at more than -$72.11 million. PACB stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.21 billion, with total debt at $939.06 million. Shareholders hold equity totaling $250.56 million.
Let’s look briefly at Pacific Biosciences of California Inc. (PACB) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 36.26% to suggest the stock is trending Neutral, with historical volatility in this time period at 65.65%.
The stock’s 5-day moving average is $12.30, reflecting a -9.61% or -$1.27 change from its current price. PACB is currently trading -11.56% above its 20-day SMA, +36.77% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by unch and SMA200 by+84.54%.
Stochastic %K and %D was 15.19% and 14.29% and the average true range (ATR) pointed at 0.72. The RSI (14) points at 39.63%, while the 14-day stochastic is at 19.19% with the period’s ATR at 0.70. The stock’s 9-day MACD Oscillator is pointing at -0.85 and -1.02 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for PACB stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate PACB as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is PACB’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $13.00 and a high of $19.00, with their median price target at $15.00. Looking at these predictions, the average price target given by analysts is for Pacific Biosciences of California Inc. (PACB) stock is $15.17.
